Prazolin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prazolin

Prazolin is a medicinal product whose active ingredient is Omeprazole, primarily classified as a Proton Pump Inhibitor (PPI). This synthetic compound is used to powerfully and sustainably reduce the amount of acid produced in the stomach.


Quick Facts

Property Description
Active Ingredient Omeprazole
Form Delayed-release capsules (Enteric-coated)
Pharmacological Class Proton Pump Inhibitor (PPI)
Common Purpose Sustained gastric acid suppression
Origin Synthetic compound

What Type of Medicine is Prazolin (Omeprazole)?

Prazolin belongs to the Proton Pump Inhibitor (PPI) pharmacological class, representing the most potent group of medicines available for gastric acid suppression. It is broadly categorized as an anti-secretory agent because its core function is to suppress the natural secretion of acid in the digestive system. Omeprazole's primary function is to decrease the amount of acid produced in the stomach, confirming its role as an acid-reducing agent. This efficacy is clinically recognized for managing conditions associated with excess acidity.

Composition and Specialized Dosage Form

The active ingredient in Prazolin is Omeprazole, a synthetic compound that is a substituted benzimidazole. The medicine is commonly administered through the oral route in the form of delayed-release capsules (also called enteric-coated capsules). This specialized formulation is a distinguishing feature, ensuring the active ingredient is protected from degradation by stomach acid until it can be absorbed effectively in the small intestine. The use of specialized enteric coating is necessary for effective absorption.

General Therapeutic Purpose

The general therapeutic purpose of Prazolin is to achieve and maintain sustained control over gastric acidity. It works by permanently turning off the specific enzyme system—the H^+K^+-ATPase or "proton pump"—in the cells lining the stomach. This targeted action results in a prolonged anti-secretory effect, lowering the overall acid level. The resulting reduced acidity is the general benefit, which allows the body to manage conditions where excess acid is the primary source of irritation or damage, such as persistent heartburn.

What side effects are possible with Prazolin?

The official safety profile for Prazolin (Omeprazole) is structured according to regulatory classifications, detailing possible adverse reactions by frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are classified as Common (ge 1/100 to <1/10) and primarily involve the gastrointestinal and nervous systems. These include headache, abdominal pain, diarrhea, constipation, flatulence, and nausea or vomiting. Less frequent reactions, categorized as Uncommon, include dizziness, insomnia, somnolence, and certain skin reactions like rash or pruritus. Rare reactions (ge 1/10,000 to <1/1,000) documented in labeling include specific hypersensitivity reactions and disorders of the blood and lymphatic system, such as thrombocytopenia.

Documented Safety Patterns and Serious Events

The regulatory profile highlights several safety characteristics associated with the duration of use. Long-term use (e.g., three months or longer) is officially noted as being associated with the potential for Hypomagnesemia (low serum magnesium) and, after one year or more, an increased risk of bone fracture (hip, wrist, or spine) and the development of benign fundic gland polyps. The official label also documents the occurrence of serious but rare events, including Acute Tubulointerstitial Nephritis and Severe Cutaneous Adverse Reactions.

Population and General Constraints

The safety profile for pediatric patients (1 to 16 years) is generally similar to adults, although fever and respiratory system events were the most frequently reported adverse events in studies for that population. The official label also states that symptomatic relief from Prazolin does not exclude the presence of gastric malignancy, and the reduction in gastric acidity may interfere with certain diagnostic tests by increasing Chromogranin A (CgA) levels.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the documented presentations and required emergency actions for an overdose of Prazolin (Omeprazole), as stated in official government regulatory documents.

Documented Overdose Manifestations

Official labeling indicates that documented symptoms of overdosage, sometimes involving doses up to 900 mg, are generally mild and transient. No serious clinical outcome has been consistently reported in humans, but immediate medical attention is still required for any suspected overdose.

Overdose manifestations that have been documented across regulatory sources primarily affect the central nervous system (CNS) and the gastrointestinal (GI) system, and include:

  • CNS Effects: Headache, drowsiness, and confusion.
  • GI Effects: Nausea, vomiting, diarrhea, and abdominal pain.
  • Other Manifestations: Tachycardia (rapid heartbeat) and dry mouth.

Required Emergency Actions

It is officially mandated that any suspected overdosage requires seeking immediate medical attention or contacting emergency services. The treatment of overdosage is strictly defined as symptomatic and supportive.

Regulatory information explicitly states that no specific antidote for omeprazole is known. Furthermore, due to the drug's high protein binding, standard hemodialysis is considered ineffective for overdose management.

Therapeutic Uses of Prazolin

Main Therapeutic Uses

Prazolin belongs to a class of medications known as alpha-blockers. It is primarily utilized in clinical practice to manage cardiovascular conditions and certain symptomatic issues related to the prostate.

Cardiovascular Management

The primary application of Prazolin is in the treatment of hypertension (high blood pressure). It works by relaxing the smooth muscles in the walls of the blood vessels, which allows blood to flow more easily through the body. Lowering blood pressure is a key component in reducing the long-term risk of cardiovascular events such as strokes and myocardial infarctions.

In some cases, it may also be used as part of a broader strategy to manage congestive heart failure, particularly when used in combination with other classes of medications like diuretics or cardiac glycosides.

Benign Prostatic Hyperplasia (BPH)

Prazolin is frequently indicated for the management of urinary symptoms associated with Benign Prostatic Hyperplasia, a non-cancerous enlargement of the prostate gland. By relaxing the muscle fibers in the prostate and the neck of the bladder, the medication helps to improve urinary flow and reduce symptoms such as:

  • Hesitancy or difficulty starting urination
  • Weak urinary stream
  • The sensation of incomplete bladder emptying
  • Frequent or urgent need to urinate

Raynaud's Phenomenon

Secondary applications of Prazolin include the treatment of Raynaud's phenomenon. In this condition, the small arteries that supply blood to the skin narrow excessively in response to cold or stress. Prazolin helps to maintain peripheral blood flow, potentially reducing the frequency and severity of discoloration and discomfort in the fingers and toes.

Potential Benefits

  • Targeted Action: Unlike some blood pressure medications that affect the heart rate, Prazolin primarily targets the vascular smooth muscle.
  • Symptomatic Relief: It provides significant relief from the physical discomfort associated with prostate enlargement, improving the overall quality of life.
  • Metabolic Neutrality: Clinical observations suggest that Prazolin generally does not have a negative impact on blood lipid profiles or glucose metabolism, making it a viable option for patients with concurrent metabolic concerns.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prazolin?

Eligibility for Prazolin (Omeprazole) is strictly defined by regulatory health authorities and depends on patient history, age, and existing medical conditions.


Absolute Contraindications

Official prescribing information states that Prazolin must not be used by certain populations:

  • Patients with a known hypersensitivity to Omeprazole, any component of the formulation, or to other substituted benzimidazoles (the drug class).
  • Patients who are concurrently receiving medicinal products that contain Nelfinavir.

Age- and Condition-Based Eligibility

Population Group Eligibility Status (Regulatory Wording)
Infants Contraindicated for use in children under 1 year of age.
Pediatric Patients Established use in children 1 year and older for specific conditions (e.g., GERD); use not established for Duodenal Ulcers or ZES.
Pregnancy/Lactation Use during pregnancy is conditional; use during lactation is generally not recommended.
Hepatic Impairment Requires conditional use/caution; a lower dose may be sufficient as noted in labeling.

For adults, a symptomatic response to Prazolin does not preclude the presence of gastric malignancy, which requires additional specialist follow-up. For patients with impaired renal function, no dosage adjustment is typically required.

What should I know about interactions with other medicines?

Prazolin (Prazosin) is an alpha-blocker that may interact with various medications and substances, potentially leading to increased side effects, primarily hypotension (low blood pressure), especially upon standing (orthostatic hypotension). It is crucial to inform your healthcare provider of all prescription, over-the-counter (OTC) medicines, herbal remedies, and supplements you are taking.

Medications That Increase Hypotension Risk

Co-administration of Prazolin with other drugs that lower blood pressure can significantly increase the risk of dizziness, lightheadedness, and fainting, particularly when starting treatment or increasing the dose.

Drug Category Examples of Interacting Medicines
Other Antihypertensives Beta-blockers, Calcium Channel Blockers (e.g., Amlodipine), ACE Inhibitors, Diuretics
Erectile Dysfunction (ED) Drugs Sildenafil, Tadalafil, Vardenafil
Alpha-Blockers (Other) Doxazosin, Terazosin, Tamsulosin, Alfuzosin

Other Significant Interactions

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Certain NSAIDs (e.g., indomethacin) may reduce the blood pressure-lowering effect of Prazolin.
  • Highly Protein-Bound Drugs: Prazolin is highly bound to plasma proteins and may interact with other highly protein-bound drugs, requiring close monitoring.
  • Alcohol: Consuming alcohol while taking Prazolin can intensify the dizzy and drowsy side effects and increase the risk of hypotension; therefore, alcohol intake should be avoided or strictly limited.

If you are scheduled for cataract surgery, notify your ophthalmologist that you are taking or have previously taken Prazolin, as alpha-blockers have been associated with Intraoperative Floppy Iris Syndrome (IFIS).

Mechanism of Action

Alpha-1 Adrenergic Receptor Blockade

Prazolin functions as an antagonist that selectively blocks Alpha-1 (alpha1) adrenergic receptors found on the surface of smooth muscle cells, interfering with signals carried by the neurotransmitter norepinephrine. This molecular action initiates a mechanistic cascade that affects smooth muscle tone and the circulatory system.


Modulating Vascular and Urinary Tract Tone

This receptor blockade is observed in the peripheral blood vessels (arteries and veins) and in the lower urinary tract (bladder neck and prostate capsule). By preventing signals that cause contraction, Prazolin results in the relaxation of these muscle tissues. This mechanism causes the widening of blood vessels (vasodilation) and is associated with a decrease in the physical resistance to blood flow.


Central Noradrenergic Influence

In addition to its major peripheral effects, the mechanism of Prazolin also involves interacting with noradrenergic pathways within the Central Nervous System (CNS). This engagement is linked to the modulation of signaling associated with sympathetic outflow and the body's state of arousal, which constitutes part of the drug's overall profile of physiological changes.

Dosage and Administration Information

Prazolin (Omeprazole) is administered via the oral route for standard maintenance and outpatient therapy, or through intravenous (IV) infusion when oral administration is not clinically feasible. The administration protocol is defined by established guidelines to ensure the medicine's proper delivery.

Administration Protocol

Field Instruction Summary
Dosing Schedule Dosing for most adult uses (e.g., healing erosive esophagitis) typically ranges from 20 mg to 40 mg once daily. Higher regimens, such as those for Zollinger-Ellison Syndrome, may require up to 360 mg daily, administered in divided doses.
Timing Oral doses are generally taken before eating to optimize the medicine's delivery profile.
Preparation Delayed-release capsules and tablets must be swallowed whole and must not be crushed or chewed, as this preserves the enteric coating necessary for absorption. The IV powder requires reconstitution and dilution before use.
Duration The course of use is specified as either short-term (e.g., 2 to 8 weeks for acute healing) or long-term maintenance for chronic suppression.

Procedural Constraints

Administration guidelines establish the use of Prazolin within specific parameters. The necessity to swallow the dosage unit whole is a primary procedural constraint that preserves the integrity of the delayed-release formulation. Standard dosing guidelines also mandate that if a once-daily dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next scheduled dose; compensation by taking a double dose is not directed.

Population-Specific Use

Dosing requires consideration for patient characteristics. Dosing parameters include review and possible reduction in patients with hepatic impairment. Use in pediatric patients at least 1 year of age is indicated for specific short-term uses with dosing determined by patient weight.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prazolin


Evidence for Use in Acid Reflux and Heartburn Symptoms (GERD)

Prazolin was explored in research focusing on the study of patient experiences related to Gastroesophageal Reflux Disease (GERD), including frequent heartburn and acid regurgitation. The research structures used included short-term and long-term Randomized Controlled Trials (RCTs) and observational studies. Research examined outcomes related to physical discomfort and patient-reported outcomes. Short-term trials described the measured patterns where participants documented their experiences, while long-term studies monitored these populations for patterns of symptom occurrence.

Evidence for Healing Tissue Damage (Erosive Esophagitis and Ulcers)

Research involving Prazolin explored patient populations affected by conditions such as erosive esophagitis (EE) and ulceration of the duodenum and stomach. Researchers used endoscopic criteria to measure the proportion of patients who achieved a specific mucosal healing status in initial trials. For ulcers, Prazolin was studied as a component of multi-drug combination regimens where the objective was to study bacterial outcomes (for H. pylori). Findings for EE described the sustained preservation of measured healing status in maintenance trials.

What Research Gaps and Uncertainties Remain

While short-term evidence is substantial for key indications, there is limited information for long-term outcomes beyond the initial maintenance of healing or symptom control. Follow-up durations were limited in many studies, meaning long-term effects are not fully established. Furthermore, comparative evidence is lacking for definitive long-term assessment against all therapeutic alternatives, and evidence quality may vary across studies involving complex comorbidities or specific patient subgroups.

Frequently Asked Questions (FAQ)

Common questions about Prazolin (FAQ)

Q: How long does it take for Prazolin to start working or to feel the full benefit?

The official product information indicates that the acid-reducing effect of Prazolin begins within one hour of taking the dose. However, achieving the maximum acid-suppressing effect generally takes about 4 days of continuous daily treatment. The onset of acid-reducing activity may precede the full clinical benefit reported by users.

Q: Is Prazolin a long-term medicine, or is it typically used for short periods?

Prazolin is indicated for both short-term and long-term use, depending on the condition being managed. For acute conditions like healing erosive damage, it is typically used for a short course of several weeks. It is also prescribed for long-term use, such as maintaining the healing of the esophagus or managing rare, severe acid-producing conditions.

Q: Does Prazolin have any effect on absorption of nutrients, like Vitamin B12 or iron?

Official warnings state that Prazolin may affect the body's ability to absorb certain nutrients due to the reduction in stomach acid. Vitamin B12 deficiency is noted as a risk with prolonged daily use, particularly for three years or longer. Prazolin can also interfere with the absorption of certain products, such as iron salts. Patients are generally advised to discuss all supplements with their healthcare provider.

Q: Can taking Prazolin increase the risk of infections like C. difficile?

Official safety information indicates that therapy with medications in the class of Prazolin may be associated with an increased risk of a type of severe diarrhea called Clostridium difficile-associated diarrhea ( CDAD). This risk is especially noted in hospitalized patients. Unusual or persistent gastrointestinal symptoms should be reported to a healthcare professional.

Q: Is Prazolin available over-the-counter ( OTC) or only by prescription?

Prazolin is available in both prescription and over-the-counter ( OTC) forms. The OTC product is typically a 20 mg dose used for the treatment of frequent heartburn in adults, while prescription strengths and indications cover a wider range of conditions.

Q: Can Prazolin cause or contribute to constipation or diarrhea?

Official adverse reaction data shows that both diarrhea and constipation are reported among the most common side effects of Prazolin. These are common gastrointestinal effects associated with the medication's use.

Q: What are the common side effects that usually go away after the body adjusts to Prazolin?

Official labeling lists common side effects, such as headache, abdominal pain, diarrhea, and nausea. While these are frequently reported, regulatory information does not specify which of these common effects are expected to subside or 'go away' as the body adjusts to the medication.

Q: What are the signs or symptoms of the serious but rare side effect of low magnesium ( hypomagnesemia)?

Prazolin's official warnings note a potential for low magnesium levels ( hypomagnesemia) with prolonged use. Symptoms reported in association with low magnesium include muscle cramps or pain, tremors, or an unusually fast or irregular heartbeat. The decision for monitoring magnesium levels during long-term use is made by a healthcare provider.

Q: Does Prazolin need to be taken before or after a meal?

Official drug administration instructions advise that Prazolin delayed-release capsules should generally be taken before eating (e.g., before the first meal of the day). This timing is recommended to help ensure the medication is absorbed optimally.

Q: Are there any interactions between Prazolin and herbal supplements?

Official drug interaction warnings explicitly mention that taking Prazolin with the herbal supplement St. John's Wort (Hypericum perforatum) can reduce the effectiveness of Prazolin. Patients are generally advised to discuss all supplements with their healthcare provider.

Q: What happens if I stop taking Prazolin suddenly?

Regulatory documents state that when Prazolin is discontinued, the stomach's acid-secreting activity returns gradually to normal. This return typically occurs over a period of 3 to 5 days as the body replaces the inhibited enzyme.

Q: Does Prazolin affect mood, anxiety, or depression?

While rare, official post-marketing reports have identified occurrences of Central Nervous System ( CNS) effects. These include insomnia (trouble sleeping) and psychiatric symptoms in severely ill patients, such as agitation, depression, and reversible confused states.

Q: Can Prazolin cause a metallic or unusual taste in the mouth?

Official reports from clinical trials, particularly those where Prazolin was used as part of a multi-drug regimen (e.g., for H. pylori), have listed taste perversion (a strange or metallic taste) as a possible adverse reaction.

Q: Is it true that taking Prazolin can cause or increase the risk of stomach polyps?

Yes, official warnings indicate that the long-term use of Prazolin has been associated with the development of benign fundic gland polyps. These are generally considered non-cancerous changes to the stomach lining that can occur over time.

Q: What is the typical dose for the treatment of GERD?

According to official guidelines, the typical dose for adults treating symptomatic GERD (Gastroesophageal Reflux Disease) without erosive damage is 20 mg once daily for a course of up to four weeks.

Q: What is the risk of having a drug interaction if I take Prazolin with other medicines for anxiety or depression?

Official drug interaction information cautions that Prazolin can potentially slow down the elimination of other medicines metabolized by certain liver enzymes (called Cytochrome P450). Because Prazolin may affect how the body processes these other medications, there is a potential for altered concentrations.

Q: Does Prazolin have a risk of rebound acid hypersecretion if I stop taking it?

When Prazolin is stopped, the acid-suppressing effect gradually wears off as the body replaces the inhibited enzyme. Official information states that acid-secreting activity returns gradually over several days, which is the underlying cause of the patient concern commonly referred to as 'rebound' symptoms.

Q: Why does Prazolin require an enteric coating (delayed release)?

Prazolin requires a special enteric coating because the active ingredient is acid labile, meaning it is quickly destroyed by the acid in the stomach. The coating protects the medicine from the stomach acid, allowing it to pass into the small intestine where it can be absorbed and become fully effective.

How should Prazolin be stored and disposed of?

How to Store and Dispose of Prazolin

Official regulatory guidelines mandate specific conditions for storing Prazolin (Omeprazole delayed-release capsules) to protect the sensitive formulation.


Storage Requirements

Prazolin must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). The product requires protection from moisture and light and must be kept in its original, tightly closed container.

  • Do not freeze and avoid excess heat, such as storage in a bathroom.
  • Always store the medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused capsules should be disposed of via an official drug take-back program or collection site. If no program is available, follow the specific procedure of mixing the capsules (do not crush) with an undesirable substance before sealing and discarding in household trash. Do not flush the medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prazolin found in:

A-Z Index: